Kyoto, Japan – A key determinant of successful immunotherapies is immune cells targeting the pathology with high specificity. CiRA scientists are using iPS cell technology to make a large batch of immune cells for immunotherapies. However, retaining the antigen specificity remains a challenge. A new study by the CiRA Associate Professor Shin Kaneko laboratory reports a method that solves this problem.